Topics
Glioblastoma | Treatment | Clinical trials | Bevacizumab and other angiogenesis inhibitors
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Bevacizumab
Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto
Y, Imai R, Kuranari Y, Tohmoto K, Hasegawa Y, Akasaki Y, Murayama
Y, Miyake K, Sasaki H.
An exploratory
prospective phase II study of preoperative neoadjuvant bevacizumab
and temozolomide for newly diagnosed glioblastoma.
J
Neurooncol. 2024 Jan 31. doi:
10.1007/s11060-023-04544-8. PMID:
38291182. Interventional
study. ˍ
Motamed-Sanaye A, Mortezaei A, Afshari AR, Saadatian Z, Faraji AH,
Sheehan JP, Mokhtari AM.
Angiogenesis
inhibitors effects on overall survival and progression-free
survival in newly diagnosed primary glioblastoma multiforme: a
meta-analysis of twelve randomized clinical trials.
J
Neurooncol. 2024 Dec 5. doi:
10.1007/s11060-024-04865-2. PMID:
39636552. Meta-analysis˰
ˍ